New combo attack on recurrent brain tumors shows promise in early trial

NCT ID NCT02800486

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests a new way to deliver the cancer drug cetuximab directly into the brain's arteries, along with mannitol to open the blood-brain barrier, plus targeted radiation. It is for adults with recurrent glioblastoma or other aggressive brain tumors that have high levels of a protein called EGFR. The goal is to see if this combination can stop tumor growth and improve survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
cetuximab (Erbitux) and mannitol, given directly into the brain's arteries, plus targeted radiation
What this could lead to
If it works, this could offer a new treatment option for people with recurrent brain cancers that have come back after standard therapy.
What could go wrong
This is a small, early-phase trial with only 37 participants, so results may not apply to everyone. The treatment involves direct infusion into brain arteries and radiation, which carry risks like brain swelling or damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANAPLASTIC ASTROCYTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Lenox Hill Brain Tumor Center

    RECRUITING

    New York, New York, 10075, United States

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.